U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118696) titled 'Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease' on July 25.
Brief Summary: RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.
Study Start Date: Feb. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Pulmonary TB
Intervention:
DRUG: Extra 600mg of Rifampicin
Intervention group participants will receive standard treatment (RHZE), plus an optimised regimen consisting of RIfampicin at 20 mg/kg (addi...